Research

Mission

Immunotherapy represents the key promising area of novel therapeutic approaches to cancer.

Within the CRPP project, we aim at establishing and expanding the concepts of bispecific antibodies and chimeric antigen receptor (CAR) T cells as cornerstones of a “targeted therapy development and technology immunotherapeutic platform” in Zurich that includes (i) monoclonal antibody engineering, (ii) CAR cell engineering, (iii) in vivo modeling and 3D imaging of CAR T cell traveling and target cell killing; and (iv) profiling of immune cell responses.

We will explore these technologies in two “targeted therapy lead disease focus programs”, one on brain tumors and one on hematologic stem cell malignancies.